MOSAIC cohort: describing clinical outcomes in patients with mpox

MOSAIC cohort: describing the clinical and virological characteristics of mpox virus infection

MOSAIC is a European, multi-country, multi-centre cohort whose aim is to describe the clinical and virological outcomes of patients infected with the mpox virus treated or not treated with tecovirimat (or other antiviral drugs). The MOSAIC study was set up in response to the unprecedented mpox epidemic that began in May 2022 in generally non-endemic countries, with the aim of describing clinical and virological outcomes in patients with this infection.

The University of Oxford (the sponsor of MOSAIC), Geneva University Hospitals (the sponsor’s representative in Switzerland) and ANRS Emerging infectious diseases (the sponsor’s representative in the European Union/European Economic Area) developed the MOSAIC protocol at the request of the European Medicines Agency‘s Clinical Trials Coordination Group.

This cohort was funded as part of the European Commission’s MPX-RESPONSE project, by DGOS and during the ANRS MIE Flash MPX call for projects.

See the list of publications:

• Clinical characterisation and outcomes of human clade IIb mpox virus disease – a European multicentre observational cohort study (MOSAIC) – 3 Jan 2025, Clinical Infectious Diseases
• MOSAIC: A cohort study of human mpox virus disease – 12 Dec 2023, Wellcome Open Research
• MOSAIC : une cohorte européenne sur la variole humaine Mpox. Enjeux de la recherche clinique pendant les épidémies [MOSAIC: a European cohort study of human Mpox – the challenges of clinical research in outbreaks] – 1 Feb 2023, Virologie